BEDFORD, Mass.–(BUSINESS WIRE)–lt;a href="" target="_blank"gt;$OCULlt;/agt; lt;a href="" target="_blank"gt;#OCUTXlt;/agt;–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the first quarter ended March 31, 2019 and provided a business update. “This is an exciting time at Ocular Therapeutix and it has been a very productive first quarter,” said Antony Mattessich, President and Chief Executive Officer.

Source link